Literature DB >> 8733373

Safety of long-term high-dose minocycline in the treatment of acne.

V Goulden1, D Glass, W J Cunliffe.   

Abstract

Minocycline is widely used as a second-line antimicrobial for acne vulgaris. Some patients require doses of up to 200 mg daily to control their acne. To assess the long-term safety of minocycline when used at higher doses, 700 patients treated with minocycline at doses of 100 mg daily, 100/200 mg on alternate days and 200 mg daily, were recruited. The mean duration of treatment was 10.5 months. Side-effects were monitored and full blood count, blood urea, electrolytes and liver function tests were carried out on 200 of the 700 patients. Side-effects were recorded in 13.6%, and included vestibular disturbance, candida infection, gastrointestinal disturbance, cutaneous symptoms (pigmentation, pruritus, photosensitive rash and urticaria) and benign intracranial hypertension. Pigmentation was the only side-effect found to be significantly increased in patients taking higher doses of minocycline, as compared with lower doses (P < 0.01). All patients with pigmentation had taken a total cumulative dose of over 70 g. No significant abnormalities were found in any of the haematological and biochemical profiles. We conclude that minocycline, at doses of up to 200 mg/day, is safe, long-term, for acne, when such doses are clinically necessary.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733373     DOI: 10.1111/j.1365-2133.1996.tb06972.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  44 in total

1.  [Skin blackish hyperpigmentation in 3 patients].

Authors:  O Bock; U Mrowietz; R Gläser
Journal:  Hautarzt       Date:  2002-06       Impact factor: 0.751

2.  Doxycycline induced intracranial hypertension.

Authors:  J Lochhead; J S Elston
Journal:  BMJ       Date:  2003-03-22

Review 3.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

Review 4.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

5.  Minocycline and doxycycline, but not other tetracycline-derived compounds, protect liver cells from chemical hypoxia and ischemia/reperfusion injury by inhibition of the mitochondrial calcium uniporter.

Authors:  Justin Schwartz; Ekhson Holmuhamedov; Xun Zhang; Gregory L Lovelace; Charles D Smith; John J Lemasters
Journal:  Toxicol Appl Pharmacol       Date:  2013-09-05       Impact factor: 4.219

6.  Efficacy and Safety Evaluation of High-density Intense Pulsed Light in the Treatment of Grades II and IV Acne Vulgaris as Monotherapy in Dark-skinned Women of Child Bearing Age.

Authors:  Ajay J Deshpande
Journal:  J Clin Aesthet Dermatol       Date:  2018-04-01

7.  A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice.

Authors:  L F S Bastos; A Angusti; M C Vilaça; L A Merlo; E B Nascimento; L T S Rocha; A M Godin; A G R Solano; S Jarussophon; E A Nunan; Y Konishi; M M Coelho
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

8.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Concurrence of Stevens-Johnson Syndrome and Bilateral Parotitis after Minocycline Therapy.

Authors:  Jimi Yoon; Seung Hun Lee; Tae-Heung Kim; Deok-Jin Choi; Jin-Pyeong Kim; Tae-Jin Yoon
Journal:  Case Rep Dermatol       Date:  2010-06-01

10.  Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2.

Authors:  Marcus Kernt; Aljoscha S Neubauer; Kirsten H Eibl; Armin Wolf; Michael W Ulbig; Anselm Kampik; Cristoph Hirneiss
Journal:  Clin Ophthalmol       Date:  2010-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.